Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers.

× No keyword cloud information.

13 in total

Review 1. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.

Authors: S Moncada; J R Vane
Journal: Pharmacol Rev Date: 1978-09 Impact factor: 25.468

Review 2. Measurements of platelet interaction with components of the vessel wall in flowing blood.

Authors: K S Sakariassen; R Muggli; H R Baumgartner
Journal: Methods Enzymol Date: 1989 Impact factor: 1.600

Review 3. Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.

Authors: Antonio Tello-Montoliu; Masafumi Ueno; Dominick J Angiolillo
Journal: Future Cardiol Date: 2011-05

4. The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin.

Authors: P Fontana; P Alberts; K S Sakariassen; H Bounameaux; J-P Meyer; A Santana Sorensen
Journal: J Thromb Haemost Date: 2011-10 Impact factor: 5.824

Review 5. Role of platelets and antiplatelet therapy in cardiovascular disease.

Authors: Masafumi Ueno; Murali Kodali; Antonio Tello-Montoliu; Dominick Joseph Angiolillo
Journal: J Atheroscler Thromb Date: 2011-03-18 Impact factor: 4.928

6. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis.

Authors: A J Cayatte; Y Du; J Oliver-Krasinski; G Lavielle; T J Verbeuren; R A Cohen
Journal: Arterioscler Thromb Vasc Biol Date: 2000-07 Impact factor: 8.311

Review 7. Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases.

Authors: Kjell S Sakariassen; Peteris Alberts; Pierre Fontana; Jessica Mann; Henri Bounameaux; Alexandra Santana Sorensen
Journal: Future Cardiol Date: 2009-09

Review 8. Prostanoid and isoprostanoid pathways in atherogenesis.

Authors: Domenico Praticò
Journal: Atherosclerosis Date: 2008-04-29 Impact factor: 5.162

9. Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation.

Authors: Séverine Roger; Marc Pawlowski; Aïda Habib; Martine Jandrot-Perrus; Jean Philippe Rosa; Marijke Bryckaert
Journal: FEBS Lett Date: 2004-01-02 Impact factor: 4.124

Review 10. Variability in responsiveness to oral antiplatelet therapy.

Authors: Dominick J Angiolillo
Journal: Am J Cardiol Date: 2009-02-02 Impact factor: 2.778

3 in total

Review 1. Antiplatelet therapy: targeting the TxA2 pathway.

Authors: P Fontana; A Zufferey; Y Daali; J-L Reny
Journal: J Cardiovasc Transl Res Date: 2013-12-19 Impact factor: 4.132

Review 2. Novel antiplatelet agents in acute coronary syndrome.

Authors: Francesco Franchi; Dominick J Angiolillo
Journal: Nat Rev Cardiol Date: 2014-10-07 Impact factor: 32.419

3. Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.

Authors: Fabiana Rollini; Antonio Tello-Montoliu; Ronakkumar Patel; Andrew Darlington; Ryan E Wilson; Francesco Franchi; Ana Muñiz-Lozano; Bhaloo Desai; Norbert Bender; Kjell S Sakariassen; Dominick J Angiolillo
Journal: J Thromb Thrombolysis Date: 2014 Impact factor: 2.300

3 in total